Results 121 to 130 of about 23,486 (164)
Efficient Small-Molecule Reversal Agents for Anticoagulant Fondaparinux. [PDF]
ACS Pharmacol Transl SciCarbajo D +5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expert Review of Cardiovascular Therapy, 2009
Fondaparinux is a synthetic pentasaccharide belonging to a new group of anticoagulants that inhibit thrombin formation by inhibiting Factor Xa, which is located at the crossing of both the intrinsic and extrinsic pathways. It has a favorable pharmacokinetic profile, and its effect is predictable and the drug does not need platelet monitoring.
Eduard Shantsila
exaly +3 more sources
Fondaparinux is a synthetic pentasaccharide belonging to a new group of anticoagulants that inhibit thrombin formation by inhibiting Factor Xa, which is located at the crossing of both the intrinsic and extrinsic pathways. It has a favorable pharmacokinetic profile, and its effect is predictable and the drug does not need platelet monitoring.
Eduard Shantsila
exaly +3 more sources
Drugs of the Future, 2002
Fondaparinux (Org-31540 / SR-90107A) is a new drug chemically synthesized for treatment and prophylaxis of thromboembolic disease. Fondaparinux is a selective inhibitor of activated factor X. Its structure is the copy of the heparin pentasaccharide sequence, the shortest chain required for antithrombin inhibition of activated factor X without ...
Susan J, Keam, Karen L, Goa
+7 more sources
Fondaparinux (Org-31540 / SR-90107A) is a new drug chemically synthesized for treatment and prophylaxis of thromboembolic disease. Fondaparinux is a selective inhibitor of activated factor X. Its structure is the copy of the heparin pentasaccharide sequence, the shortest chain required for antithrombin inhibition of activated factor X without ...
Susan J, Keam, Karen L, Goa
+7 more sources
Current Pharmaceutical Design, 2005
Fondaparinux is the first drug from the pentassaccharide factor X inhibitor class of anticoagulants to be approved for clinical use. It has been shown to be effective in the prevention of deep vein thrombosis in patients undergoing major orthopaedic surgery of the lower limbs. The drug is also being evaluated for use in the acute coronary syndromes and
Kiat T, Tan, Gregory Y H, Lip
openaire +2 more sources
Fondaparinux is the first drug from the pentassaccharide factor X inhibitor class of anticoagulants to be approved for clinical use. It has been shown to be effective in the prevention of deep vein thrombosis in patients undergoing major orthopaedic surgery of the lower limbs. The drug is also being evaluated for use in the acute coronary syndromes and
Kiat T, Tan, Gregory Y H, Lip
openaire +2 more sources
Drugs & Aging, 2008
Fondaparinux is a synthetic pentasaccharide that inhibits thrombin formation and thrombus development via selective antithrombin mediated inhibition of factor Xa. The complete bioavailability (100%) and elimination half-life of approximately 17 hours allows once-daily administration of fondaparinux.
Singh Sindhu, Peter Silberstein
openaire +3 more sources
Fondaparinux is a synthetic pentasaccharide that inhibits thrombin formation and thrombus development via selective antithrombin mediated inhibition of factor Xa. The complete bioavailability (100%) and elimination half-life of approximately 17 hours allows once-daily administration of fondaparinux.
Singh Sindhu, Peter Silberstein
openaire +3 more sources
Monitoring fondaparinux with the Sonoclot
Blood Coagulation & Fibrinolysis, 2007Fondaparinux is a new anticoagulant that interacts with antithrombin III and activated coagulation factor X resulting in an inhibition of the coagulation system. It has been successful in doses of 2.5 mg for thromboprophylaxis as well as in higher therapeutic doses of 5-7.5 mg.
Caroline U, Nilsson, Martin, Engström
openaire +2 more sources
Thrombosis and Haemostasis, 2014
HIT complicating fondaparinux prophylaxis: fondaparinux-dependent platelet activation as a marker for fondaparinux-induced HIT -
Jonathan Manheim +2 more
openaire +1 more source
HIT complicating fondaparinux prophylaxis: fondaparinux-dependent platelet activation as a marker for fondaparinux-induced HIT -
Jonathan Manheim +2 more
openaire +1 more source
Fondaparinux in Pulmonary Embolism
New England Journal of Medicine, 2004To the Editor: The Matisse Investigators (Oct. 30 issue)1 conclude that fondaparinux is as effective as intravenous unfractionated heparin in the treatment of hemodynamically stable pulmonary embol...
openaire +2 more sources
Journal of the American Academy of Orthopaedic Surgeons, 2004
Alexander G G, Turpie +3 more
openaire +2 more sources
Alexander G G, Turpie +3 more
openaire +2 more sources